Document Detail

The treatment of a thyrotropin-secreting pituitary macroadenoma with octreotide in twin pregnancy.
MedLine Citation:
PMID:  12201834     Owner:  NLM     Status:  MEDLINE    
TSH-secreting pituitary tumours are rare but difficult to treat due to a combination of refractory hyperthyroidism and low surgical cure rates. We describe the case of a 21-year-old woman who, despite twin pregnancy, became euthyroid and had dramatic tumour shrinkage on octreotide treatment. To our knowledge, this is the first description of the use of octreotide for a TSH-secreting pituitary adenoma throughout pregnancy.
G Blackhurst; M W Strachan; D Collie; A Gregor; P F X Statham; J E R Seckl
Related Documents :
12114694 - Vascularity in nontumorous human pituitaries and incidental microadenomas: a morphometr...
20062694 - Management of pituitary adenoma with mass effect in pregnancy: a case report.
15050094 - Dependence of fetal hairs and sebaceous glands on fetal adrenal cortex and possible con...
4356264 - Quantitative relations of fetal and maternal pitiutary-adrenal systems.
15038904 - Previous miscarriages influence ivf and intracytoplasmatic sperm injection pregnancy ou...
16671874 - Periodontitis and plasma c-reactive protein during pregnancy.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Clinical endocrinology     Volume:  57     ISSN:  0300-0664     ISO Abbreviation:  Clin. Endocrinol. (Oxf)     Publication Date:  2002 Sep 
Date Detail:
Created Date:  2002-08-30     Completed Date:  2002-10-16     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0346653     Medline TA:  Clin Endocrinol (Oxf)     Country:  England    
Other Details:
Languages:  eng     Pagination:  401-4     Citation Subset:  IM    
Endocrinology Unit, Molecular Medicine Centre, University of Edinburgh, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenoma / drug therapy*,  secretion
Antineoplastic Agents, Hormonal / therapeutic use*
Octreotide / therapeutic use*
Pituitary Neoplasms / drug therapy*,  secretion
Pregnancy Complications, Neoplastic / drug therapy*
Thyrotropin / secretion*
Reg. No./Substance:
0/Antineoplastic Agents, Hormonal; 83150-76-9/Octreotide; 9002-71-5/Thyrotropin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Malnutrition, zinc supplementation and catch-up growth: changes in insulin-like growth factor I, its...
Next Document:  Neonatal thyrotoxicosis and maternal infertility in thyroid hormone resistance due to a mutation in ...